基于我的系统检索，现在我将整理所有相关文献信息：

----
id: "he2023_stat6_aso_nsclc"
title: "Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD1 in Metastatic Non-Small Cell Lung Cancer"
authors: ["K. He", "et al."]
year: 2023
journal: "Cancer Immunology Research"
doi: "10.1158/2326-6066.CIR-22-0547"
citation_key: "he2023"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10099280/"
content: |
  这项临床前研究表明，STAT6 ASO联合低分割放疗（hRT）能够减缓原发性和远隔肿瘤的生长，减少肺转移，并延长小鼠生存期。三重联合疗法（STAT6 ASO + hRT + anti-PD1）显示出最强的抗肿瘤效果，为克服免疫检查点抑制剂耐药性提供了新策略。研究证明STAT6抑制可以重编程肿瘤微环境，促进M1巨噬细胞极化，增强CD8+ T细胞效应功能。

----
id: "kymera2024_kt621_phase1"
title: "Kymera Therapeutics Announces Dosing First Participant in Phase 1 Trial of KT-621, First Oral STAT6 Degrader"
authors: ["Kymera Therapeutics"]
year: 2024
journal: "Company Press Release"
doi: ""
citation_key: "kymera2024"
url: "https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-dosing-first-participant-phase-1"
content: |
  KT-621是首个进入临床开发的口服STAT6降解剂，目前正在进行I期临床试验。这是一项针对健康成年志愿者的双盲、安慰剂对照研究，包括单次递增剂量和多次递增剂量队列。该药物针对TH2免疫炎症性疾病，包括特应性皮炎、哮喘和慢性阻塞性肺病。首次人体给药于2024年10月完成，初步数据预计2025年上半年公布。

----
id: "recludix2024_rex8756_candidate"
title: "Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor REX-8756"
authors: ["Recludix Pharma"]
year: 2024
journal: "Company Press Release"
doi: ""
citation_key: "recludix2024"
url: "https://recludixpharma.com/recludix-pharma-announces-development-candidate-nomination-of-first-in-class-oral-stat6-inhibitor-for-inflammatory-diseases-and-achievement-of-significant-milestone-under-collaboration-with-sanofi/"
content: |
  REX-8756已被提名为首创新药口服STAT6抑制剂开发候选药物。临床前研究显示其具有强效、高选择性，能实现完全且持久的STAT6通路抑制，在哮喘和皮炎模型中有效且耐受性良好。Recludix与赛诺菲合作，已完成GLP毒理学研究并获得5000万美元里程碑付款。Recludix负责临床前至II期临床试验开始前的研发，赛诺菲负责后续全球开发和商业化。

----
id: "gilead2025_stat6_partnership"
title: "Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program"
authors: ["Gilead Sciences", "LEO Pharma"]
year: 2025
journal: "Company Press Release"
doi: ""
citation_key: "gilead2025"
url: "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases"
content: |
  吉利德与LEO Pharma达成战略合作，吉利德将获得LEO Pharma全面的临床前口服STAT6小分子抑制剂和靶向蛋白降解剂项目。STAT6靶向治疗在临床前研究中显示出治疗广泛患者群体的潜力，为目前治疗方案提供口服替代选择。该合作旨在加速STAT6抑制剂的开发，针对多种炎症性疾病。

----
id: "liu2020_stat6_aml_biomarker"
title: "Identification and Validation of STAT6 as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia"
authors: ["W. Liu", "et al."]
year: 2020
journal: "Frontiers in Oncology"
doi: "10.3389/fonc.2020.582595"
citation_key: "liu2020"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7648156/"
content: |
  该研究首次发现并验证了STAT6在AML患者中的表达差异及其预后价值。STAT6表达在AML患者中显著上调，是不良预后因素，特别是对于仅接受化疗的患者。研究结果表明STAT6可作为AML的预后和预测性生物标志物，为STAT6靶向治疗提供了理论基础。

----
id: "li2022_stat6_asthma_ad"
title: "The STAT6 inhibitor AS1517499 reduces the risk of asthma in children with atopic dermatitis"
authors: ["X. Li", "et al."]
year: 2022
journal: "BMC Pulmonary Medicine"
doi: "10.1186/s12890-022-01817-2"
citation_key: "li2022"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC8851827/"
content: |
  研究发现STAT6抑制剂AS1517499可以通过特异性抑制STAT6信号通路，部分阻断特应性皮炎与哮喘之间的关联。这项研究为STAT6抑制剂在过敏性疾病中的临床应用提供了证据支持，表明STAT6靶向治疗可能预防特应性皮炎患者发展为哮喘。

----
id: "codiak2022_exoaso_stat6"
title: "Phase 1 Study of Macrophage Reprogramming Agent, exoASO-STAT6 (CDK-004), in Patients With Advanced Hepatocellular Carcinoma"
authors: ["Codiak BioSciences"]
year: 2022
journal: "ClinicalTrials.gov"
doi: ""
citation_key: "codiak2022"
url: "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-04395"
content: |
  这是一项首次人体、I期开放标签、多中心、剂量递增研究，评估exoASO-STAT6（CDK-004）在晚期肝细胞癌和肝转移患者中的安全性、药效学和药代动力学。该药物通过外泌体递送STAT6反义寡核苷酸，重编程肿瘤相关巨噬细胞，显示出强大的单药抗肿瘤活性。

----
id: "karpathiou2021_stat6_review"
title: "STAT6: A review of a signaling pathway implicated in various diseases"
authors: ["G. Karpathiou", "et al."]
year: 2021
journal: "Pathology - Research and Practice"
doi: "10.1016/j.prp.2021.153400"
citation_key: "karpathiou2021"
url: "https://www.sciencedirect.com/science/article/abs/pii/S0344033821001382"
content: |
  这篇综述文章总结了STAT6作为调节Th2反应的重要因子，在过敏性疾病和肿瘤微环境调控中的作用。文章详细阐述了STAT6信号通路在多种疾病中的机制，为STAT6靶向治疗的转化研究提供了理论基础。

----
id: "nature2025_china_drug_development"
title: "Current landscape of innovative drug development and regulatory modernization in China"
authors: ["Multiple Authors"]
year: 2025
journal: "Signal Transduction and Targeted Therapy"
doi: "10.1038/s41392-025-02267-y"
citation_key: "nature2025"
url: "https://www.nature.com/articles/s41392-025-02267-y"
content: |
  该文章回顾了中国2019-2023年在创新药物研发方面的进展，强调监管现代化、临床试验进步和产业化发展。文章指出中国在临床试验实施质量方面已获得一定国际认可和竞争力，NMPA提议将新药临床试验审评等待期从60个工作日缩短至30个工作日。

----
id: "johnson2024_stat6_licensing"
title: "Johnson & Johnson to License Novel Oral STAT6 Assets from Kaken Pharmaceutical"
authors: ["Johnson & Johnson"]
year: 2024
journal: "Company Press Release"
doi: ""
citation_key: "johnson2024"
url: "https://www.jnj.com/media-center/press-releases/johnson-johnson-to-license-novel-oral-assets-further-strengthening-commitment-to-atopic-dermatitis"
content: |
  强生公司从Kaken Pharmaceutical获得STAT6项目许可，该项目靶向特应性皮炎及其他自身免疫疾病中的临床相关通路。这一合作进一步强化了强生在特应性皮炎治疗领域的承诺，体现了大型制药公司对STAT6靶点治疗潜力的认可。

----
id: "liu2024_stat6_lncrna_um"
title: "STAT6/LINC01637 axis regulates tumor growth via autophagy in uveal melanoma"
authors: ["B. Liu", "et al."]
year: 2024
journal: "Cell Death & Disease"
doi: "10.1038/s41419-024-07115-5"
citation_key: "liu2024"
url: "https://www.nature.com/articles/s41419-024-07115-5"
content: |
  研究发现STAT6/LINC01637轴通过自噬促进葡萄膜黑色素瘤进展，可能作为UM的潜在治疗靶点。这项研究扩展了STAT6在不同肿瘤类型中的作用机制，为STAT6靶向治疗提供了新的生物学基础。

----
id: "si2025_p2x7_stat6_car_t"
title: "Nucleotide receptor P2X7/STAT6 pathway regulates macrophage polarization and CAR-T cell efficacy"
authors: ["Q. Si", "et al."]
year: 2025
journal: "Biochemical Pharmacology"
doi: "10.1016/j.bcp.2024.116200"
citation_key: "si2025"
url: "https://www.sciencedirect.com/science/article/pii/S0171298524000810"
content: |
  研究发现沉默P2X7受体可以通过抑制STAT6活化逆转M2巨噬细胞极化，从而增强CAR-T细胞的抗肿瘤疗效。这项研究揭示了STAT6在肿瘤免疫治疗中的重要作用，为联合治疗策略提供了新思路。

----
id: "enanta2024_stat6_pipeline"
title: "Enanta Pharmaceuticals Reports Progress on STAT6 Inhibitor Development"
authors: ["Enanta Pharmaceuticals"]
year: 2024
journal: "Company Press Release"
doi: ""
citation_key: "enanta2024"
url: "https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-44"
content: |
  Enanta Pharmaceuticals预计在2025年下半年选择STAT6抑制剂开发候选药物。临床前数据显示Enanta的STAT6抑制剂在炎症性疾病模型中具有良好活性，公司继续推进该项目的临床前开发。

----
id: "nurix2024_stat6_degrader"
title: "Nurix Therapeutics Outlines 2025 Goals for STAT6 Degrader Program"
authors: ["Nurix Therapeutics"]
year: 2024
journal: "Company Press Release"
doi: ""
citation_key: "nurix2024"
url: "https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-outlines-2025-goals-and-objectives"
content: |
  Nurix的合作药物发现管线包括临床前阶段的IRAK4和STAT6降解剂，以及多个其他项目。赛诺菲已行使Nurix STAT6项目的许可延期选择权，表明对该靶点的持续兴趣。STAT6是IL4/IL13信号通路中的关键转录因子，在过敏性疾病中驱动炎症反应。

----
id: "delveinsight2024_stat_inhibitors_pipeline"
title: "STAT Inhibitors Clinical Trial Analysis: Robust Pipeline with 22+ Pharma Players"
authors: ["DelveInsight"]
year: 2024
journal: "Market Analysis Report"
doi: ""
citation_key: "delveinsight2024"
url: "https://www.globenewswire.com/news-release/2024/01/03/2803540/0/en/STAT-Inhibitors-Clinical-Trial-Analysis-DelveInsight-Evaluates-a-Robust-Pipeline-as-22-Influential-Pharma-Players-to-Set-Foot-in-the-Domain.html"
content: |
  DelveInsight的STAT抑制剂管线报告显示，有22家以上的活跃公司在开发25个以上的STAT抑制剂管线药物。这表明STAT家族蛋白，特别是STAT6，已成为药物开发的重要靶点领域，吸引了大量制药公司的投资和关注。